Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name ERBB3 Q809R
Gene Variant Detail

ERBB3 Q809R (gain of function)

Relevant Treatment Approaches HER inhibitor (Pan) HER2 Inhibitor HER3 Inhibitor Pertuzumab Trastuzumab

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 Q809R Advanced Solid Tumor sensitive HER2 Inhibitor Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor sensitive Duligotuzumab Preclinical Actionable In a preclinical study, MEHD7945A inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor sensitive Trastuzumab Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor decreased response Pertuzumab Pertuzumab Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Perjeta (pertuzumab), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor resistant Cetuximab Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor decreased response Pictilisib Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB3 (HER3) Q809R in culture demonstrated a decreased response to Pictlisib (GDC-0941), showing inhibition of proliferation and colony formation, but to a lesser degree than other therapies (PMID: 23680147). 23680147
ERBB3 Q809R Advanced Solid Tumor sensitive Mirdametinib + Pictilisib Preclinical Actionable In a preclinical study, the combination of GDC-0941 and Gomekli (mirdametinib) inhibited proliferation and colony formation in transformed cell lines expressing ERBB3 (HER3) Q809R (PMID: 23680147). 23680147